Comparative Pharmacology
Head-to-head clinical analysis: ASPARLAS versus LONSURF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPARLAS versus LONSURF.
ASPARLAS vs LONSURF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asparaginase (ASPARLAS) hydrolyzes L-asparagine to L-aspartic acid and ammonia, depleting circulating asparagine. Leukemic cells with low asparagine synthetase activity rely on exogenous asparagine; depletion inhibits protein and nucleic acid synthesis, leading to cell death.
LONSURF (trifluridine and tipiracil) is a combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil. Trifluridine incorporates into DNA and inhibits cell proliferation, while tipiracil increases trifluridine exposure by inhibiting its degradation by thymidine phosphorylase.
Intravenous (IV) or intramuscular (IM) injection: 2,500 IU/m² every 14 days as a component of multi-agent chemotherapy. Administer IV over 1-2 hours in 100 mL of 0.9% sodium chloride.
Adults: 35 mg/m2 orally twice daily on days 1-5 and 8-12 of each 28-day cycle.
None Documented
None Documented
The terminal elimination half-life is approximately 25.7 days (range 17.8–33.6 days) in children and 22.0 days in adults, allowing for dosing every 2 weeks instead of 3 times per week as with native E. coli asparaginase.
Trifluridine: terminal half-life approximately 1.4-2.1 hours; tipiracil: terminal half-life approximately 2-3 hours. Clinical context: short half-lives necessitate twice-daily dosing on Days 1-5 and 8-12 of a 28-day cycle.
Calaspargase pegol (ASPARLAS) is eliminated via the reticuloendothelial system; renal excretion is negligible (<2% unchanged), and biliary/fecal excretion has not been quantified. The pegylated asparaginase is cleared through proteolytic degradation.
Primarily renal: tipiracil is excreted unchanged in urine (approximately 50% of dose); trifluridine is eliminated via metabolism and renal excretion (as metabolites and unchanged drug). Fecal elimination accounts for <3% of total clearance.
Category C
Category C
Antineoplastic, Enzyme
Antineoplastic